Clinical outcomes of everolimus plus exemestane versus fulvestrant in patients with metastatic breast cancer after progression on cyclin-dependent kinase 4/6 inhibitors
For tens of thousands of women living with metastatic breast cancer, the arrival of cyclin-dependent kinase 4/6 inhibitors transformed a ...
